People · Operator
Named in public records as an officer, director or promoter · active 2015–2022 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kanyos Bio, Inc. | — | Biotechnology | Series A | $16.4M | $376.0M | 2015 |
| ClostraBio, Inc. | — | Other | Series A | $9.9M | $77.8M | 2022 |
Jeffrey Hubbell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Hubbell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jack Nielsen | 1 | 13 |
| Thomas Woiwode | 1 | 7 |
| Florent Gros | 1 | 4 |
| John Flavin | 1 | 4 |
| Harry Welten | 1 | 1 |
| Andre Mueller | 1 | 1 |
| Brett Newswanger | 1 | 1 |
| Cathryn Nagler | 1 | 1 |
| Oscar Buset | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.